SCM
HAE icon

Steadfast Capital Management’s Haemonetics HAE Stock Holding History

Steadfast Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-91,800
Closed -$7.36M – 90
2025
Q4 		$7.36M Buy
+91,800
New +$6.17M 0.13% 78

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Steadfast Capital Management's HAE Position: Q1 2026 in Review

Steadfast Capital Management sold out of Haemonetics (HAE) in Q1 2026, closing a stake of 91,800 shares — an estimated $7.36M sold.

Steadfast Capital Management first reported a position in HAE in Q4 2025 and held it in 1 quarter. The position peaked at $7.36M in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Steadfast Capital Management reported no remaining Haemonetics position as of Q1 2026 after selling out during the quarter.
  • Steadfast Capital Management sold 91,800 Haemonetics shares in Q1 2026, an estimated $7.36M.
  • Steadfast Capital Management first reported a position in Haemonetics in Q4 2025 and held it in 1 quarter.
  • Steadfast Capital Management's Haemonetics position peaked at $7.36M in Q4 2025.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Steadfast Capital Management's 13F filing for Q1 2026, filed 15 May 2026.